Literature DB >> 10780522

Vascular endothelial growth factor, platelet-derived endothelial cell growth factor and angiogenesis in non-small-cell lung cancer.

K J O'Byrne1, M I Koukourakis, A Giatromanolaki, G Cox, H Turley, W P Steward, K Gatter, A L Harris.   

Abstract

High microvessel density, an indirect measure of angiogenesis, has been shown to correlate with increased tumour size, lymph node involvement and poor prognosis in non-small-cell lung cancer (NSCLC). Tumour cell vascular endothelial growth factor (VEGF) and platelet-derived endothelial cell growth factor (PD-ECGF) expression correlate with angiogenesis and a poor outcome in this disease. In a retrospective study VEGF and PD-ECGF expression and microvessel density were evaluated immunohistochemically in surgically resected specimens (T1-3, N0-2) from 223 patients with operable NSCLC using the VG1, P-GF.44C and JC70 monoclonal antibodies respectively. High VEGF immunoreactivity was seen in 104 (46.6%) and PD-ECGF in 72 (32.3%) cases and both were associated with high vascular grade tumours (P= 0.009 and P= 0.05 respectively). Linear regression analysis revealed a weak positive correlation between VEGF and PD-ECGF expression in cancer cells (r= 0.21; P = 0.002). Co-expression of VEGF and PD-ECGF was not associated with a higher microvessel density than VEGF or PD-ECGF only expressing tumours. Furthermore a proportion of high vascular grade tumours expressed neither growth factor. Univariate analysis revealed tumour size, nodal status, microvessel density and VEGF and PD-ECGF expression as significant prognostic factors. Tumour size (P < 0.02) and microvessel density (P < 0.04) remained significant on multivariate analysis. In conclusion, VEGF and PD-ECGF are important angiogenic growth factors and have prognostic significance in NSCLC. Furthermore the study underlines the prognostic significance of microvessel density in operable NSCLC.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10780522      PMCID: PMC2363365          DOI: 10.1054/bjoc.1999.1129

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  38 in total

1.  Prognostic value of angiogenesis in operable non-small cell lung cancer.

Authors:  A Giatromanolaki; M Koukourakis; K O'Byrne; S Fox; R Whitehouse; D C Talbot; A L Harris; K C Gatter
Journal:  J Pathol       Date:  1996-05       Impact factor: 7.996

2.  Preliminary studies of a novel oral fluoropyrimidine carbamate: capecitabine.

Authors:  D R Budman; N J Meropol; B Reigner; P J Creaven; S M Lichtman; E Berghorn; J Behr; R J Gordon; B Osterwalder; T Griffin
Journal:  J Clin Oncol       Date:  1998-05       Impact factor: 44.544

3.  Treatment of metastatic non-small cell lung cancer.

Authors:  N van Zandwijk; G Giaccone
Journal:  Curr Opin Oncol       Date:  1996-03       Impact factor: 3.645

4.  Identification of angiogenic activity and the cloning and expression of platelet-derived endothelial cell growth factor.

Authors:  F Ishikawa; K Miyazono; U Hellman; H Drexler; C Wernstedt; K Hagiwara; K Usuki; F Takaku; W Risau; C H Heldin
Journal:  Nature       Date:  1989-04-13       Impact factor: 49.962

5.  Clinicopathologic and prognostic significance of an angiogenic factor, thymidine phosphorylase, in human colorectal carcinoma.

Authors:  Y Takebayashi; S Akiyama; S Akiba; K Yamada; K Miyadera; T Sumizawa; Y Yamada; F Murata; T Aikou
Journal:  J Natl Cancer Inst       Date:  1996-08-21       Impact factor: 13.506

6.  Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo.

Authors:  K J Kim; B Li; J Winer; M Armanini; N Gillett; H S Phillips; N Ferrara
Journal:  Nature       Date:  1993-04-29       Impact factor: 49.962

7.  Quantitation and prognostic value of breast cancer angiogenesis: comparison of microvessel density, Chalkley count, and computer image analysis.

Authors:  S B Fox; R D Leek; M P Weekes; R M Whitehouse; K C Gatter; A L Harris
Journal:  J Pathol       Date:  1995-11       Impact factor: 7.996

8.  Thymidine phosphorylase is angiogenic and promotes tumor growth.

Authors:  A Moghaddam; H T Zhang; T P Fan; D E Hu; V C Lees; H Turley; S B Fox; K C Gatter; A L Harris; R Bicknell
Journal:  Proc Natl Acad Sci U S A       Date:  1995-02-14       Impact factor: 11.205

9.  Interrelationships between microvessel density, expression of VEGF and resistance to doxorubicin of non-small lung cell carcinoma.

Authors:  M Volm; R Koomägi; J Mattern
Journal:  Anticancer Res       Date:  1996 Jan-Feb       Impact factor: 2.480

10.  Increased sensitivity to the prodrug 5'-deoxy-5-fluorouridine and modulation of 5-fluoro-2'-deoxyuridine sensitivity in MCF-7 cells transfected with thymidine phosphorylase.

Authors:  A V Patterson; H Zhang; A Moghaddam; R Bicknell; D C Talbot; I J Stratford; A L Harris
Journal:  Br J Cancer       Date:  1995-09       Impact factor: 7.640

View more
  65 in total

1.  Tumor specific activation of the VEGF/KDR angiogenic pathway in a subset of locally advanced squamous cell head and neck carcinomas.

Authors:  A Giatromanolaki; M I Koukourakis; E Sivridis; P E Thorpe; R A Brekken; S Konstantinos; G Fountzilas; K C Gatter; A L Harris
Journal:  Clin Exp Metastasis       Date:  2000       Impact factor: 5.150

2.  Imaging proliferation of ¹⁸F-FLT PET/CT correlated with the expression of microvessel density of tumour tissue in non-small-cell lung cancer.

Authors:  Wenfeng Yang; Yongming Zhang; Zheng Fu; Xiaorong Sun; Dianbin Mu; Jinming Yu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-05-12       Impact factor: 9.236

Review 3.  Immunohistochemical markers of prognosis in non-small cell lung cancer: a review and proposal for a multiphase approach to marker evaluation.

Authors:  C-Q Zhu; W Shih; C-H Ling; M-S Tsao
Journal:  J Clin Pathol       Date:  2006-08       Impact factor: 3.411

4.  Maspin, VEGF and p53 expression in small biopsies of primary advanced lung cancer and relationship with clinicopathologic parameters.

Authors:  Ahmet Bircan; Sema Bircan; Nilgun Kapucuoglu; Necla Songur; Onder Ozturk; Ahmet Akkaya
Journal:  Pathol Oncol Res       Date:  2010-03-28       Impact factor: 3.201

5.  The inhibitory effect of disease-modifying anti-rheumatic drugs and steroids on gliostatin/platelet-derived endothelial cell growth factor production in human fibroblast-like synoviocytes.

Authors:  Takuma Kusabe; Yuko Waguri-Nagaya; Tomohiro Tanikawa; Mineyoshi Aoyama; Muneyoshi Fukuoka; Masaaki Kobayashi; Takanobu Otsuka; Kiyofumi Asai
Journal:  Rheumatol Int       Date:  2005-07-01       Impact factor: 2.631

6.  Early growth response-1 induces and enhances vascular endothelial growth factor-A expression in lung cancer cells.

Authors:  Hiroaki Shimoyamada; Takuya Yazawa; Hanako Sato; Koji Okudela; Jun Ishii; Masashi Sakaeda; Korehito Kashiwagi; Takehisa Suzuki; Hideaki Mitsui; Tetsukan Woo; Michihiko Tajiri; Takahiro Ohmori; Takashi Ogura; Munetaka Masuda; Hisashi Oshiro; Hitoshi Kitamura
Journal:  Am J Pathol       Date:  2010-05-20       Impact factor: 4.307

Review 7.  Thymidine Phosphorylase in Cancer; Enemy or Friend?

Authors:  Yasir Y Elamin; Shereen Rafee; Nemer Osman; Kenneth J O Byrne; Kathy Gately
Journal:  Cancer Microenviron       Date:  2015-08-23

8.  Phosphorylated epidermal growth factor receptor and cyclooxygenase-2 expression in localized non-small cell lung cancer.

Authors:  Seok Jin Kim; Zahid N Rabbani; Fan Dong; Robin T Vollmer; Ernst-Gilbert Schreiber; Mark W Dewhirst; Zeljko Vujaskovic; Michael J Kelley
Journal:  Med Oncol       Date:  2009-02-24       Impact factor: 3.064

Review 9.  Lung cancer. 9: Molecular biology of lung cancer: clinical implications.

Authors:  K M Fong; Y Sekido; A F Gazdar; J D Minna
Journal:  Thorax       Date:  2003-10       Impact factor: 9.139

10.  Anti-vascular endothelial growth factor therapies at the crossroads: linifanib for non-small cell lung cancer.

Authors:  Hidehito Horinouchi
Journal:  Transl Lung Cancer Res       Date:  2016-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.